Corrigendum to “Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer” [Lung Cancer, 114, (December) (2017) 106–107]

The authors regret missing authors Kelly Jia, Andrew Morgan Ayers and Konstantinos Dean Boudoulas from the author list of this manuscript. This authorship is correct above. The authors would like to apologise for any inconvenience caused. Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancerLung CancerVol. 114PreviewThe use of immunotherapies has become more widespread in advanced solid and hematologic malignancies and has improved overall survival. Toxicities of these newer immunotherapies are still emerging. Atezolizumab is an FDA-approved anti-programmed death-ligand 1 (PD-L1) monoclonal antibody for metastatic non-small-cell lung cancer (mNSCLC) [1]. Clinical trials have shown favorable results [2–5]. We report a case of a patient treated with atezolizumab who presented with cardiogenic shock secondary to suspected myocarditis. Full-Text PDF